Acute graft-versus-host disease (aGVHD) is a major life-threatening complication after
allogeneic hematopoietic cell transplant. Traditional standard prophylaxis for aGVHD has …

Advances in conditioning, graft-versus-host disease (GVHD) prophylaxis and antimicrobial
prophylaxis have improved the safety of allogeneic hematopoietic cell transplantation (HCT) …

Abstract The Practice Guidelines Committee of the American Society for Transplantation and
Cellular Therapy partnered with its Transplant Infectious Disease Special Interest Group to …

Viral infections remain a major risk in immunocompromised pediatric patients, and virus-
specific T cell (VST) therapy has been successful for treatment of refractory viral infections in …

Letermovir is a relatively new antiviral for prophylaxis against cytomegalovirus (CMV) after
allogeneic hematopoietic cell transplantation (HCT). CMV-seropositive HCT recipients who …

HHV-6B reactivation affects approximately half of all allogeneic hematopoietic cell transplant
(HCT) recipients. HHV-6B is the most frequent infectious cause of encephalitis following …

Preventing viral infections at an early stage is a key strategy for successfully improving
transplant outcomes. Preemptive therapy and prophylaxis with antiviral agents have been …

Abstract Whether to choose Haploidentical (Haplo) or one-antigen mismatched unrelated
donor (1Ag-MMUD) hematopoietic cell transplantation (HCT) with post-transplant …

Abstract Human herpesvirus 6 (HHV-6) can reactivate after allogeneic hematopoietic stem
cell transplant (allo-HSCT) and may lead to severe symptoms. HHV-6–specific immune …

Severe acute and chronic graft versus host disease (GVHD) remains a major cause of
morbidity and mortality after allogeneic hematopoietic cell transplantation. Historically, cord …